CD274 and head and neck squamous cell carcinoma: Consequently, following the findings of the randomized phase 3 KEYNOTE-040 trial demonstrating that the CPS demonstrated greater sensitivity than TPS at lower threshold values in predicting pembrolizumab efficacy, CPS developed as the preferred scoring method for evaluating PD-L1 expression HNSCC [119].